UNSPSC 85573657: Destruction of left pleura, percutaneous approach

This classification denotes the group of activities that yields a surgical intervention or procedure to destruction of left pleura, percutaneous approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 0B5P3ZZ

UNSPSC 85573657 Destruction of left pleura, percutaneous approach is a Commodity code that shows little relevant recent activity under state and local procurement. The code's nominal scope—a specific surgical procedure—does not align with the work actually being solicited by public agencies in the recent opportunities block. The source records multiple state and local solicitations posted in August and September 2026, but they address occupational medical surveillance, disability medical evaluations, pharmacy benefit management, temporary health professional staffing, surgical benefit carve-outs, and emergency medical services for youth in detention—none of which involve destruction of left pleura or invasive thoracic procedures. The mismatch between the code's clinical specificity and the broad, administrative medical contracting activity in the records suggests either miscoding by issuing bodies or that this particular procedure code does not drive state and local procurement patterns.

State and local governments do not appear to solicit surgical procedures themselves through UNSPSC procurement codes; instead, they contract for medical services administration, staffing, benefit management, and facility-based care delivery. If pleural destruction services are procured at all under state and local contracts, they would typically be embedded within broader hospital service agreements, specialty center networks, or occupational health programs—not as standalone commodity line items. No issuing body has tagged a recent opportunity with this code. Vendors in clinical specialties should monitor whether this code gains traction; at present it generates no actionable market signal.